The innovative idea of a three-point transoral endoscopic approach to the anterior neck region, specifically the thyroid gland, was extensively discussed in published anatomic studies [1]. On this basis, regions providing a safe access route, without the risk of collateral damage to neural or vascular structures, have been identified. In the first attempts to reach the target area, a totally sublingual access route through the floor of the mouth was evaluated and finally abandoned owing to the lack of triangulation and the imminent risk to anatomic structures in the submandibular groove [1]. The first author of this reply then had the idea of changing the incision sites from the floor of the mouth to the oral vestibulum. Through this transoral access, an approach to the thyroid on an endoscopic basis was successfully performed for the first time in an anatomic experiment [2]. Following these anatomic studies, an experimental study on the safety and feasibility took place in pigs and was successfully completed [3]. The first successful clinical application was undertaken in a 53-year-old man on March 18, 2009, and the results were published [4]. As outlined in our more recent paper, an intensive discussion regarding all the legal and ethical aspects of a possible human application took place, and the rationale for the decision taken was outlined in that report [5]. We recommend that Dr. Benhidjeb and Prof. Stark undertake a thorough re-reading of our article as it seems that they have not understood the difference between ‘‘treatment’’ and ‘‘human experiment’’ as defined under German law. Our proof-of-concept study was not a ‘‘human experiment’’ as stated by Benhidjeb and Stark. All other issues raised in their Letter to the Editor were also raised by Benhidjeb et al. in a recent Letter to the Editor in another journal [6]. The relevant issues were extensively addressed in our reply to that letter, and the interested reader may refer to that reply, specifically with reference to the role of T. Benhidjeb, M. Stark, and the New European Surgical Academy (NESA) in the development of endoscopic minimally invasive thyroidectomy [7]. The NESA is a scientific interdisciplinary society designed to bring together ideas and solutions for surgical problems from different fields of surgery. It therefore seems abstruse when Benhidjeb and Stark state that ‘‘the NESA decided at that time not to proceed to clinical application’’ [8]. Note that it remains the responsibility of the acting scientist, the institutional review board, and the ethics committee—not a scientific society—to decide on this issue. In our report of the proof-of-concept study on eMIT [5], we outlined every complication recorded, the time of onset, and the outcome as well as the conclusions drawn from those events. This was unquestionably done in line with the relevant scientific rules because our paper passed the review process of the journal immediately, without hesitation or any mandatory revisions. The interpretations of the reported complications by Benhidjeb and Stark, notably when dealing in percentages on this small number of treated patients, is abstruse and, in our opinion, unscientific. We also reiterate that clinical application of this new and innovative approach at this stage was never recommended. The conclusion we reached T. Wilhelm (&) Department of Otolaryngology, Head/Neck and Facial Plastic Surgery, HELIOS Klinikum Borna, Rudolf-Virchow-Strasse 2, 04552 Borna, Germany e-mail: thomas.wilhelm@helios-kliniken.de